ScholarIQanswers from OpenAlex & ORCID
Daiki Ueno
ResearcherPublications, citations & collaboration network
Daiki Ueno is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Daiki Ueno have?
ScholarIQindexed works
Daiki Ueno has 97 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Daiki Ueno have?
ScholarIQcitation count
Daiki Ueno has 805 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Daiki Ueno?
ScholarIQh-index
Daiki Ueno has an h-index of 16 in OpenAlex.
What is the i10-index of Daiki Ueno?
ScholarIQi10-index
Daiki Ueno has an i10-index of 21 in OpenAlex.
What is the ORCID of Daiki Ueno?
ScholarIQorcid
The ORCID for Daiki Ueno is on the source record.
What is the OpenAlex record for Daiki Ueno?
ScholarIQopenalex
The OpenAlex for Daiki Ueno is on the source record.
What are the most-cited papers on Daiki Ueno?
ScholarIQmost cited works
Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair
Parker L. Sulkowski, Ranjini K. Sundaram, Sebastian Oeck, Christopher D. Corso, Yanfeng Liu, Seth Noorbakhsh, Monica Niger, Marta Boeke, Daiki Ueno, Aravind Kalathil, Xun Bao, Jing Li, Brian Shuch, Ranjit S. Bindra, Peter M. Glazer
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
Daiki Ueno, Masahiro Yao, Ukihide Tateishi, Ryogo Minamimoto, Kazuhide Makiyama, Narihiko Hayashi, Futoshi Sano, Takayuki Murakami, Takeshi Kishida, Takeshi Miura, Kazuki Kobayashi, Sumio Noguchi, Ichiro Ikeda, Yoshiharu Ohgo, Tomio Inoue, Yoshinobu Kubota, Noboru Nakaigawa
FH Variant Pathogenicity Promotes Purine Salvage Pathway Dependence in Kidney Cancer
Blake R. Wilde, Nishma Chakraborty, Nedas Matulionis, Stephanie Hernandez, Daiki Ueno, Michayla E. Gee, Edward D. Esplin, Karen Ouyang, Keith Nykamp, Brian Shuch, Heather R. Christofk
FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma
Noboru Nakaigawa, Keiichi Kondo, Ukihide Tateishi, Ryogo Minamimoto, Tomohiro Kaneta, Kazuhiro Namura, Daiki Ueno, Kazuki Kobayashi, Takeshi Kishida, Ichiro Ikeda, Hisashi Hasumi, Kazuhide Makiyama, Yoshinobu Kubota, Tomio Inoue, Masahiro Yao
Glutamine and the Tumor Immune Microenvironment
Izak Faiena, Daiki Ueno, Brian Shuch